Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 1200-1202 |
Aantal pagina's | 3 |
Tijdschrift | The Lancet Oncology |
Volume | 20 |
Nummer van het tijdschrift | 9 |
DOI's |
|
Status | Gepubliceerd - sep. 2019 |
Toegang tot document
Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Oncology, Vol. 20, Nr. 9, 09.2019, blz. 1200-1202.
Onderzoeksoutput: Bijdrage aan tijdschrift › Opmerking/debat
TY - JOUR
T1 - A European paediatric cancer mission
T2 - aspiration or reality?
AU - Kearns, Pamela R.
AU - Vassal, Gilles
AU - Ladenstein, Ruth
AU - Schrappe, Martin
AU - Biondi, Andrea
AU - Blanc, Patricia
AU - Eggert, Angelika
AU - Kienesberger, Anita
AU - Kozhaeva, Olga
AU - Pieters, Rob
AU - Schmiegelow, Kjeld
N1 - Funding Information: PRK reports personal fees from Bristol-Myers Squibb (BMS), Genzyme, Janssen, and AbbVie (outside the submitted work), and is president of the Society of Paediatric Oncology Europe (SIOPE) and a board member of the European Innovative Therapeutics for Children with Cancers (ITCC) network and the ACCELERATE international multistakeholder platform. GV is a board member of SIOPE; president of the ITCC network; chair of the ACCELERATE international multistakeholder platform; and adviser (does not accept personal remuneration) in paediatric oncology drug development for AstraZeneca, Bayer, BMS, Celgene, Incyte, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche/Genentech, Servier, Takeda, and Tesaro. RL is a board member of SIOPE. MS reports grants from Deutsche Krebshilfe, Bonn, Germany; reports personal fees from JazzPharma; reports personal fees, speaker's board, and support for research from Servier (outside the submitted work); and is a board member of SIOPE. AB is an advisory board member of Novartis, Celgene, Incyte, and BMS (outside the submitted work). AE is a member of a working group within the activities of the national (German) decade against cancer. AK reports a memorandum of understanding with SIOPE and PanCare. OK is employed by SIOPE. All other authors declare no competing interests.
PY - 2019/9
Y1 - 2019/9
UR - http://www.scopus.com/inward/record.url?scp=85071539272&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(19)30487-5
DO - 10.1016/S1470-2045(19)30487-5
M3 - Comment/debate
C2 - 31486360
AN - SCOPUS:85071539272
SN - 1470-2045
VL - 20
SP - 1200
EP - 1202
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 9
ER -